Cargando…
Cardiovascular magnetic resonance T2* mapping for the assessment of cardiovascular events in hypertrophic cardiomyopathy
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is associated with an increased risk of adverse cardiac events. Beyond classic risk factors, relative myocardial ischaemia and succeeding myocardial alterations, which can be detected using either contrast agents or parametric mapping in cardiovascular m...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076262/ https://www.ncbi.nlm.nih.gov/pubmed/32201584 http://dx.doi.org/10.1136/openhrt-2019-001152 |
_version_ | 1783507185728225280 |
---|---|
author | Gastl, Mareike Gruner, Christiane Labucay, Karin Gotschy, Alexander Von Spiczak, Jochen Polacin, Malgorzata Boenner, Florian Kelm, Malte Ruschitzka, Frank Alkadhi, Hatem Kozerke, Sebastian Manka, Robert |
author_facet | Gastl, Mareike Gruner, Christiane Labucay, Karin Gotschy, Alexander Von Spiczak, Jochen Polacin, Malgorzata Boenner, Florian Kelm, Malte Ruschitzka, Frank Alkadhi, Hatem Kozerke, Sebastian Manka, Robert |
author_sort | Gastl, Mareike |
collection | PubMed |
description | BACKGROUND: Hypertrophic cardiomyopathy (HCM) is associated with an increased risk of adverse cardiac events. Beyond classic risk factors, relative myocardial ischaemia and succeeding myocardial alterations, which can be detected using either contrast agents or parametric mapping in cardiovascular magnetic resonance (CMR) imaging, have shown an impact on outcome in HCM. CMR may help to risk stratify using parametric T2* mapping. Therefore, the aim of the present study was to evaluate the association of T2* values or fibrosis with cardiovascular events in HCM. METHODS: The relationship between T2* with supraventricular, ventricular arrhythmia or heart failure was retrospectively assessed in 91 patients with HCM referred for CMR on a 1.5T MR imaging system. Fibrosis as a reference was added to the model. Patients were subdivided into groups according to T2* value quartiles. RESULTS: 47 patients experienced an event of ventricular arrhythmia, 25 of atrial fibrillation/flutter and 17 of heart failure. T2*≤28.7 ms yielded no association with ventricular events in the whole HCM cohort. T2* of non-obstructive HCM showed a significant association with ventricular events in univariate analysis, but not in multivariate analysis. For the combined endpoint of arrhythmic events, there was already an association for the whole HCM cohort, but again only in univariate analyses. Fibrosis stayed the strongest predictor in all analyses. There was no association for T2* and fibrosis with heart failure. CONCLUSIONS: Decreased T2* values by CMR only provide a small association with arrhythmic events in HCM, especially in non-obstructive HCM. No information is added for heart failure. |
format | Online Article Text |
id | pubmed-7076262 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-70762622020-03-20 Cardiovascular magnetic resonance T2* mapping for the assessment of cardiovascular events in hypertrophic cardiomyopathy Gastl, Mareike Gruner, Christiane Labucay, Karin Gotschy, Alexander Von Spiczak, Jochen Polacin, Malgorzata Boenner, Florian Kelm, Malte Ruschitzka, Frank Alkadhi, Hatem Kozerke, Sebastian Manka, Robert Open Heart Heart Failure and Cardiomyopathies BACKGROUND: Hypertrophic cardiomyopathy (HCM) is associated with an increased risk of adverse cardiac events. Beyond classic risk factors, relative myocardial ischaemia and succeeding myocardial alterations, which can be detected using either contrast agents or parametric mapping in cardiovascular magnetic resonance (CMR) imaging, have shown an impact on outcome in HCM. CMR may help to risk stratify using parametric T2* mapping. Therefore, the aim of the present study was to evaluate the association of T2* values or fibrosis with cardiovascular events in HCM. METHODS: The relationship between T2* with supraventricular, ventricular arrhythmia or heart failure was retrospectively assessed in 91 patients with HCM referred for CMR on a 1.5T MR imaging system. Fibrosis as a reference was added to the model. Patients were subdivided into groups according to T2* value quartiles. RESULTS: 47 patients experienced an event of ventricular arrhythmia, 25 of atrial fibrillation/flutter and 17 of heart failure. T2*≤28.7 ms yielded no association with ventricular events in the whole HCM cohort. T2* of non-obstructive HCM showed a significant association with ventricular events in univariate analysis, but not in multivariate analysis. For the combined endpoint of arrhythmic events, there was already an association for the whole HCM cohort, but again only in univariate analyses. Fibrosis stayed the strongest predictor in all analyses. There was no association for T2* and fibrosis with heart failure. CONCLUSIONS: Decreased T2* values by CMR only provide a small association with arrhythmic events in HCM, especially in non-obstructive HCM. No information is added for heart failure. BMJ Publishing Group 2020-03-15 /pmc/articles/PMC7076262/ /pubmed/32201584 http://dx.doi.org/10.1136/openhrt-2019-001152 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Heart Failure and Cardiomyopathies Gastl, Mareike Gruner, Christiane Labucay, Karin Gotschy, Alexander Von Spiczak, Jochen Polacin, Malgorzata Boenner, Florian Kelm, Malte Ruschitzka, Frank Alkadhi, Hatem Kozerke, Sebastian Manka, Robert Cardiovascular magnetic resonance T2* mapping for the assessment of cardiovascular events in hypertrophic cardiomyopathy |
title | Cardiovascular magnetic resonance T2* mapping for the assessment of cardiovascular events in hypertrophic cardiomyopathy |
title_full | Cardiovascular magnetic resonance T2* mapping for the assessment of cardiovascular events in hypertrophic cardiomyopathy |
title_fullStr | Cardiovascular magnetic resonance T2* mapping for the assessment of cardiovascular events in hypertrophic cardiomyopathy |
title_full_unstemmed | Cardiovascular magnetic resonance T2* mapping for the assessment of cardiovascular events in hypertrophic cardiomyopathy |
title_short | Cardiovascular magnetic resonance T2* mapping for the assessment of cardiovascular events in hypertrophic cardiomyopathy |
title_sort | cardiovascular magnetic resonance t2* mapping for the assessment of cardiovascular events in hypertrophic cardiomyopathy |
topic | Heart Failure and Cardiomyopathies |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076262/ https://www.ncbi.nlm.nih.gov/pubmed/32201584 http://dx.doi.org/10.1136/openhrt-2019-001152 |
work_keys_str_mv | AT gastlmareike cardiovascularmagneticresonancet2mappingfortheassessmentofcardiovasculareventsinhypertrophiccardiomyopathy AT grunerchristiane cardiovascularmagneticresonancet2mappingfortheassessmentofcardiovasculareventsinhypertrophiccardiomyopathy AT labucaykarin cardiovascularmagneticresonancet2mappingfortheassessmentofcardiovasculareventsinhypertrophiccardiomyopathy AT gotschyalexander cardiovascularmagneticresonancet2mappingfortheassessmentofcardiovasculareventsinhypertrophiccardiomyopathy AT vonspiczakjochen cardiovascularmagneticresonancet2mappingfortheassessmentofcardiovasculareventsinhypertrophiccardiomyopathy AT polacinmalgorzata cardiovascularmagneticresonancet2mappingfortheassessmentofcardiovasculareventsinhypertrophiccardiomyopathy AT boennerflorian cardiovascularmagneticresonancet2mappingfortheassessmentofcardiovasculareventsinhypertrophiccardiomyopathy AT kelmmalte cardiovascularmagneticresonancet2mappingfortheassessmentofcardiovasculareventsinhypertrophiccardiomyopathy AT ruschitzkafrank cardiovascularmagneticresonancet2mappingfortheassessmentofcardiovasculareventsinhypertrophiccardiomyopathy AT alkadhihatem cardiovascularmagneticresonancet2mappingfortheassessmentofcardiovasculareventsinhypertrophiccardiomyopathy AT kozerkesebastian cardiovascularmagneticresonancet2mappingfortheassessmentofcardiovasculareventsinhypertrophiccardiomyopathy AT mankarobert cardiovascularmagneticresonancet2mappingfortheassessmentofcardiovasculareventsinhypertrophiccardiomyopathy |